What is the recommended protocol for recalling blood components and managing recipients when a donor is found HIV-positive after donation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Recall Protocol for HIV-Positive Blood Donors

When a blood donor tests HIV-positive after donation, immediately quarantine all previously distributed blood components from that donor, notify all consignees (hospitals/transfusion services) who received products from prior donations, and initiate recipient notification and testing protocols.

Immediate Actions Required

Blood Establishment Responsibilities

Blood centers must implement written procedures for managing HIV-positive donor discoveries 1. The protocol follows this sequence:

  • Quarantine all products: Immediately quarantine any remaining whole blood, blood components, Source Plasma, or Source Leukocytes from the HIV-positive donor that are still in inventory 1, 2

  • Perform confirmatory testing: When a repeat donor tests repeatedly reactive for HIV antibody, conduct more specific testing using a licensed confirmatory test (e.g., Western blot or supplemental assay) 1

  • Retrieve repository samples: Test archived samples from the donor's previous donations using more sensitive assays (e.g., Cobas Taqman HIV-1 test) to determine if prior donations were infectious 3

  • Notify all consignees: Contact every hospital or transfusion service that received blood products from this donor's previous donations so appropriate action can be taken 1, 2

Hospital/Transfusion Service Responsibilities

Hospitals must quarantine any remaining products and initiate recipient notification 2:

  • Immediately quarantine any blood products from the implicated donor still in inventory
  • Review transfusion records to identify all recipients of products from this donor
  • Notify the attending physicians of affected patients
  • Arrange for recipient HIV testing and counseling

Recipient Management Protocol

Testing Timeline

Recipients should be tested for HIV-1 antibody using the following schedule 4:

  • Baseline: Immediately upon notification (if not already tested pre-transfusion)
  • 3 months post-transfusion
  • 6 months post-transfusion
  • 12 months post-transfusion

This extended follow-up is critical because most HIV-infected persons seroconvert within 6-12 weeks, but surveillance through 12 months ensures detection of any delayed seroconversion 4.

Clinical Benefits of Early Detection

Early identification of HIV infection in recipients enables three critical interventions 4:

  1. Early medical intervention: Initiate antiretroviral therapy and prophylaxis for opportunistic infections based on CD4+ counts before symptoms develop
  2. Prevention of secondary transmission: Counsel recipients to prevent transmission to sexual partners, needle-sharing partners, and (for women) vertical transmission to infants
  3. Identification of other at-risk recipients: If the recipient tests positive and the donor is confirmed as the source, other recipients from the same donor can be traced and stored tissue retrieved

Important Clinical Considerations

Immunosuppressed transplant recipients can mount HIV antibody responses 4. Despite concerns about immunosuppressive therapy affecting antibody production, studies confirm that HIV-antibody response is not delayed in transplant recipients receiving antirejection therapy, which primarily affects cellular immunity 4.

Multiple HIV-positive recipients from the same donor strongly implicates donor-source transmission 4. While linking HIV to transfusion can be challenging when recipients have other risk factors or received multiple blood products, identifying multiple infected recipients from one donor provides strong evidence of transmission.

Lookback Investigation

Donor Sample Testing

When available, test stored blood or lymphoid samples from the donor using 4:

  • HIV-1 p24 antigen assays
  • More sensitive nucleic acid testing (NAT) with lower detection limits
  • Viral sequencing to confirm transmission linkage if recipients test positive

Documentation Requirements

The investigation must document 1, 2:

  • All products distributed from the HIV-positive donor
  • All consignees notified and dates of notification
  • All recipients identified and notification status
  • All testing results for recipients
  • Any confirmed transmissions

Critical Pitfalls to Avoid

Do not assume negative NAT results eliminate all risk 3. A documented case in France showed HIV transmission despite individual NAT-negative results, demonstrating that donations during the pre-ramp-up phase of HIV infection can escape even highly sensitive screening (detection limit 23 copies/mL) 3.

Do not delay notification due to incomplete recipient information. Even if recipients cannot be immediately located, initiate the notification process and document all attempts 1, 2.

Do not limit follow-up to 6 months. The 12-month testing window is essential to capture any delayed seroconversions 4.

Regulatory Framework

This protocol is mandated by FDA regulations requiring blood establishments to maintain written procedures for HIV-positive donor management 1. Hospitals participating in Medicare/Medicaid must comply with parallel requirements for recipient notification 2. These federal regulations establish minimum standards that must be followed regardless of state laws, though implementation should align with existing state statutes 4.

References

Related Questions

According to the US Preventive Services Task Force, which screening test is recommended for a 35-year-old male with a new male sex partner, inconsistent condom use, normal blood pressure, BMI of 19, and an unremarkable physical exam?
Is a negative rapid HIV finger‑prick antibody test performed 80 days after a possible exposure sufficient to rule out infection?
What is the recommended HIV post‑exposure prophylaxis regimen for a 17‑year‑old male who had unprotected receptive anal intercourse with a male partner last night, has never been tested for HIV, and does not know the partner’s HIV status?
Which antiretroviral (HIV) medications can cause clinically significant acid‑base disturbances, and how should these disturbances be monitored and managed?
What are the recommended two‑drug and three‑drug regimens for HIV post‑exposure prophylaxis, including dosing for adults and children?
For a 185‑lb patient with well‑controlled obstructive sleep apnea on CPAP who has persistent dry mouth, is currently taking zolpidem (Ambien) 10 mg nightly, and previously failed doxepin, should I switch to another dual‑orexin receptor antagonist or try eszopiclone (Lunesta) given the high copay?
Given a TSH of 0.351 mIU/L, should the TSH be repeated in 4–6 weeks?
Is it safe to take omeprazole 40 mg twice daily together with famotidine 40 mg at night?
How should a normal physical examination be documented?
What are the causes of recurrent vulvovaginal candidiasis in a woman?
Can Lexapro (escitalopram) exacerbate hypermobile Ehlers‑Danlos syndrome, postural orthostatic tachycardia syndrome (POTS), or mast‑cell activation syndrome (MCAS) symptoms?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.